

The background of the slide is a photograph of a modern cannabis dispensary. The interior features light-colored wood paneling on the walls and shelving units. A central counter holds a large white vase with green plants. In the background, there are colorful circular murals on the wall and a display case filled with various cannabis products. The overall atmosphere is clean and contemporary.

.Jushi

The Next Generation Cannabis Platform

Cautionary Statement Regarding Forward-Looking Statements



This Presentation may contain “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws, including Canadian securities legislation and United States (“U.S.”) securities legislation (collectively, “forward-looking information”) which are based upon the Company’s current internal expectations, estimates, projections, assumptions and beliefs. All information, other than statements of historical facts, included in this report that address activities, events or developments that the Company expects or anticipates will or may occur in the future constitutes forward-looking information. Forward-looking information is often identified by the words, “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes, among others, information regarding: future business strategy; competitive strengths, goals, expansion and growth of the Company’s business, operations and plans, including new revenue streams; the refinancing or securing other sources of liquidity to meet debt repayment obligations; the integration and benefits of recently acquired businesses or assets; roll out of new operations; the implementation of certain research and development; the application for additional licenses and the grant of licenses that will be or have been applied for; the expansion or construction of certain facilities; the reduction in the number of our employees; the expansion into additional U.S. and international markets; any potential future legalization of adult-use and/or medical marijuana under U.S. federal law; expectations of market size and growth in the U.S. and the states in which the Company operates; expectations for other economic, business, regulatory and/or competitive factors related to the Company or the cannabis industry generally; and other events or conditions that may occur in the future.

Readers are cautioned that forward-looking information is not based on historical facts but instead is based on reasonable assumptions and estimates of the management of the Company at the time they were provided or made and such information involves known and unknown risks, uncertainties, including our ability to continue as a going concern, and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as applicable, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others: the benefits and timeline for consummating the expected benefits of the Continuance; the limited operating history of the industry and the Company; risks related to managing the growth of the Company including completed, pending or future acquisitions or dispositions, including potential future impairment of goodwill or intangibles acquired and/or post-closing disputes; risks related to the continued performance, expansion and/or optimization of existing operations; risks related to capitalizing on Virginia's transition to an adult-use cannabis market; risks related to the anticipated openings of additional dispensaries or relocation of existing dispensaries subject to licensing approval; the Company’s historical operating losses and negative operating cash flows; increasing competition in the industry; risks inherent in an agricultural business, such as the effects of natural disasters; reliance on the expertise and judgment of senior management of the Company; risks associated with cannabis products manufactured for human consumption including potential product recalls; limited research and data relating to cannabis; constraints on marketing products; risk of litigation; insurance-related risks; public opinion and perception of the cannabis industry; risks related to the economy generally; fraudulent activity by employees, contractors and consultants; risks relating to the Company’s current amount of indebtedness; risks related to not being able to reduce or refinance its debt obligations; risks related to litigation or other disputes; reliance on key inputs, suppliers and skilled labor, and third party service provider contracts; reliance on manufacturers and contractors; risks of supply shortages or supply chain disruptions; risks relating to pandemics and forces of nature; risks related to the enforceability of contracts; risks related to inflation, the rising cost of capital, and stock market instability; risks relating to U.S. regulatory landscape and enforcement related to cannabis, including political risks; risks relating to anti-money laundering laws and regulation; cannabis-related tax risks and challenges from governmental authorities with respect to the Company’s application for Employee Retention Tax Credits (ERTC); other governmental and environmental regulation; risks related to proprietary intellectual property and potential infringement by third parties; sales of a significant amount of shares by existing shareholders; the limited market for securities of the Company; risks relating to the need to raise additional capital either through debt or equity financing; costs associated with the Company being a publicly-traded company and a U.S. and Canadian filer; risks related to co-investment with parties with different interests to the Company; conflicts of interest and related party transactions; cybersecurity risks; and risks related to the Company’s critical accounting policies and estimates. Refer to Part I - Item 1A. Risk Factors in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 31, 2026, for more information.

Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information will prove to be accurate as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on the forward-looking information contained in this presentation or other forward-looking statements made by the Company. Forward-looking information is provided and made as of the date of this presentation and the Company does not undertake any obligation to revise or update any forward-looking information or statements other than as required by applicable law. Unless the context requires otherwise, references in this presentation to “Jushi,” “Company,” “we,” “us” and “our” refer to Jushi Holdings Inc. and our subsidiaries..

Operational Results Advisory

Any statements regarding the Company's estimated operations following Q2 2026, do not present all information necessary for an understanding of the Company's current or future results of operations and undue reliance should not be placed on such estimates, all of which are "forward-looking information" and "forward-looking statements" subject to the risks and uncertainties described above.

Jushi at a Glance – August 2026



Market Type	State	Number of Operating Stores	Vertical Presence	Cultivation & Processing Square Footage
MED	PA	18	Yes	123k
MED**	VA	6	Yes	93k
AU	OH	7	Yes	17k
AU	MA	2	Yes	50k
AU	NV	3	Yes	40k
AU	IL	4	--	--
AU	NJ	1	--	--
AU	CA	1	--	--
--	Total	42	5	323k

~\$272M

LTM Q2 2026 Revenue

~\$51M

LTM Q2 2026 Adj. EBITDA

1,226

Jushi Employees*

8

Operating Markets

* As of June 30, 2026; **Anticipated adult-use sales starting on July 1, 2027

H1 2026 Selected Company Highlights



Completion of \$160 Million Non-Dilutive Debt Refinancing in March 2026

- Three-year, 12.5% coupon term loan with interest-only payments and no equity dilution with participation from Jushi's two largest shareholders
- Single minimum cash covenant provides enhanced operational and financial flexibility

State-Licensed Medical Cannabis Rescheduled to Schedule III Eliminating Section 280E for Qualifying State-Licensed Medical Cannabis Operations beginning in April 2026

- Meaningfully improves Jushi's financial profile through elimination of 280E for qualifying medical operations, reducing ongoing tax expense and creating potential for retrospective tax relief

Applications Submitted for DEA Registration of State-Licensed Medical Cannabis Operations in May 2026

- Submitted DEA registration applications under the newly established federal Schedule III framework
- Positions Jushi to participate in the evolving federal framework for the manufacture, distribution and dispensing of medical cannabis

Virginia Adult-Use Cannabis Legislation Passed in June 2026

- Unlocks one of Jushi's largest growth opportunities, with adult-use sales expected to commence July 1, 2027 and Jushi favorably positioned to participate as a legacy medical operator

Completed Redomicile from British Columbia to Nevada in July 2026 Following Shareholder Approval in June 2026

- Aligns Jushi's corporate structure with its U.S. operations, enhancing strategic flexibility and positioning the company for future capital markets opportunities
- Following the redomicile, Jushi continues to trade under the ticker symbol "JUSH" on the CSE and OTCQX


H2 2026 and 2027 Growth Priorities



TOP PRIORITY MARKETS FOR CAPITAL ALLOCATION

1

Virginia



- Position retail and inventory levels for anticipated adult-use sales starting on July 1, 2027
- Existing grower processor facility expansion and improvements
- New warehouse design and planning for 2027 build-out

2

Pennsylvania



- Optimize grower processor facility to shorten the timeline required to bring additional capacity online once there is greater visibility into adult-use sales
- Evaluate potential store relocations to improve profitability and prepare for potential adult-use sales

3

Ohio



- Continue accelerating revenue growth across new stores
- Target the acquisition of additional retail licenses to reach state-permitted retail license cap
- Expand cultivation and processing facilities depending on market conditions and cost of capital

H2 2026 and 2027 Growth Priorities (Cont'd)



1

VIRGINIA: ADULT-USE OPPORTUNITY HAS POTENTIAL TO ACCELERATE BUSINESS GROWTH

- Virginia adult-use cannabis sales expected to commence July 1, 2027
- Retail infrastructure is currently prepared to support adult-use sales with only modest incremental capital investment required
- Expanding cultivation capacity at current facility adding 2 more flowering rooms within the existing footprint, increasing canopy by ~33%
- Adding hydrocarbon extraction capabilities to support a broader mix of higher-value concentrate products, process more throughput and expand product selection for patients and consumers
- In the design phase for a new ~65,000 square foot warehouse expansion that would roughly double canopy footprint and support expanded processing capabilities
 - Evaluating more traditional financing alternatives with commercial banks that can offer lower cost of capital
 - Expect the expansion project construction-related capital spending to occur in Q4 2026 to Q4 2027
- Also exploring second site cultivation opportunities to provide additional biomass supply in a cost-efficient manner, which we expect to provide a highly attractive return on investment opportunity

H2 2026 and 2027 Growth Priorities (Cont'd)



1

VIRGINIA: ONE OF THE MOST ATTRACTIVE NEAR-TERM STATE-LEVEL CATALYSTS IN CANNABIS

Virginia Market Opportunity

- Population: 8.9 million⁽¹⁾
- First adult-use cannabis market in the South
- Clear timeline to commencement of sales July 1, 2027
- Jushi to hold first mover advantage in a historically limited license market
- Based on comparable adult-use cannabis market flips (e.g., New Jersey), Virginia could see its cannabis market sales grow more than 3x+ initially

Virginia HSA II

- HSA II* license is one of most coveted licenses in U.S.
- Approximately 2.6 million people in HSA II
 - Smallest geographic and most densely populated HSA in Virginia⁽²⁾
 - Located within the affluent Northern Virginia / Washington, D.C. metropolitan market
 - Median age of 38 years⁽²⁾
- Jushi permitted up to 70,000 square feet of canopy under adult-use bill; Owned real estate provides flexibility for ample expansion
- 6 operational retail locations distributed across HSA in strategically selected highly-trafficked, attractive commercial corridors

* Existing Virginia medical market comprised of 5 Health Service Areas (HSA)

H2 2026 and 2027 Growth Priorities (Cont'd)



2 PENNSYLVANIA: PREPARING THOUGHTFULLY FOR FUTURE ADULT-USE SALES

- Preparing for potential adult-use expansion while remaining prudent in use of capital
 - Funding all activities with cash from balance sheet, withholding from using add'l third-party financing until there is clear regulatory direction
- Evaluating potential store relocations to improve retail profitability and prepare for potential adult-use sales

Three phase cultivation expansion

- Phase 1 (near completion): converting a legacy flower room into 3 modernized flowering rooms, effectively creating new productive capacity
- Phases 2 and 3 (future): reengineering unutilized space with potential to add ~4 additional flowering rooms and increase total canopy by ~40%
 - Ramping up Phase 2 by completing targeted prework and other sequencing activities while limiting capital deployment at this stage
 - Approach is intended to shorten the timeline required to bring capacity online once there is greater visibility into adult-use sales

3 OHIO: RETAIL FIRST APPROACH WITH OPTIONALITY TO DRIVE VERTICAL MARGINS

- Prioritized expansion in retail footprint in 2024 – 2025 and are actively evaluating acquisitions for more stores to reach the state-permitted retail license cap
- Canopy increased ~2.4x year-over-year in 2025, allowing us to expand production capacity
- In design phase for warehouse expansion to add additional canopy; would only proceed if market conditions and cost of capital are favorable
 - Goal is to increase verticality in market to levels comparable with other vertical markets in which we operate to increase margins

Virginia Highlights

PRIMARY MARKET DRIVERS



Scan to see more about
Virginia on your phone.
<https://jushico.com/va-highlights>

Vertically Integrated with 6 Medical Dispensaries in extremely desirable areas of Northern Virginia

6

Dispensaries

~93k

Sq. Ft. Facility

~8.9M

VA State Population⁽¹⁾

~2.6M

Health Service Area (“HSA”) II
Population⁽³⁾

~93.7k

Total unique patient visits from Jushi
within HSA II (as of 06/30/2026)⁽⁴⁾

Pennsylvania Highlights

PRIMARY MARKET DRIVERS



Scan to see more about
Pennsylvania on your phone.
<https://jushico.com/pa-highlights>

Vertically Integrated with 18 Medical Dispensaries (out of 198 Operational⁽⁵⁾; ~9.1% of market)

18

Dispensaries

~123k

Sq. Ft. Facility

~13.1M

PA Population⁽⁶⁾

~439k

Market Active Patients⁽⁷⁾
(~3.4% of Total Pop)

Ohio Highlights

PRIMARY MARKET DRIVERS

Vertically Integrated with 7 Dual Use Dispensaries

~11.9M

OH State Population⁽⁸⁾

7

Dispensaries

~17k

Sq. Ft. Facility



MA, NV, IL, CA and NJ Highlights

SECONDARY MARKET DRIVERS

MASSACHUSETTS

Vertically Integrated with 2
Dispensaries

2

Dispensaries

~50k

Sq. Ft. Facility

NEVADA

Vertically Integrated with 3
Dispensaries

3

Dispensaries

~40k

Sq. Ft. Facility

ILLINOIS

4

Dispensaries

NEW JERSEY

1

Dispensary

CALIFORNIA

1

Dispensary

The Jushi Retail Experience


LEADING OMNICHANNEL EXPERIENCE

Jushi provides patients and customers with a frictionless retail experience.



Retail Design

Our carefully designed and inviting cannabis experience welcomes all levels of consumers.



Digital

Place your order online for express pickup, curbside or delivery and download our app for exclusive savings. Available in select markets.



Products

We offer our customers an expansive variety of house products across all major categories and price points.

Next-Level Store Design

LEADING OMNICHANNEL EXPERIENCE



- Sleek Mid-Century Design
- Ample Parking
- Great Signage
- Express Pickups Where Permitted



- Built for Medical or Adult-use
- Multiple Points of Sale
- UX In-Store Design
- Beyond TV



Jushi's E-Commerce Platform – Our Largest Store

JUSHI'S LEADING OMNICHANNEL EXPERIENCE



Scan to see our e-commerce platform
<https://jushico.com/e-com>

Industry leading digital platform facilitating online ordering, dispensary discovery and customer engagement.

~69%



Order Online (Q2 26)

~23%

Menu Conversion Rate (Q2 26)

~\$82

Avg. Cart Size (Q2 26)



Hello Club Rewards Program & App

JUSHI'S LEADING OMNICHANNEL EXPERIENCE

The Hello Club app provides our valued customers with a rewards program, in-app shopping and weekly app-exclusive deals. It's our most valuable retention tool.

~268k

App Downloads

~\$204

Avg Mo. Spend / Visiting App User

~537k

Total Loyalty Earning Members



Comprehensive Suite of Brands Across Portfolio



JUSHI'S LEADING OMNICHANNEL EXPERIENCE



Scan to check out the brands now on your phone!
<https://jushico.com/our-brands>

hijinks



FLOWER, PRE-ROLLS, LIVE ROSIN
VAPES & CONCENTRATES

FLOWER FOUNDRY



PACKAGED FLOWER

SÈCHE



PACKAGED FLOWER & PRE-ROLLS

TASTEOLGY



INFUSED CHEWS & CHOCOLATES

THE LAB



VAPES & CONCENTRATES

VAN GOLDEN



LIVE RESIN
VAPES & CONCENTRATES

Comprehensive Suite of Brands Across Portfolio



JUSHI'S LEADING OMNICHANNEL EXPERIENCE



Scan to check out the brands now on your phone!
<https://jushico.com/our-brands>

SHAYO



VAPES & INFUSED CHEWS

Nira⁺ Medicinals



TINCTURES, CAPSULES, TOPICALS & RSO

THE BANK



FLOWER & PRE-ROLLS

CARM'S DELIGHT BITES



INFUSED CHOCOLATE BITES

UNCOMMON KIND



RSO, LIVE RESIN & ROSIN
INFUSED CHEWS

Markets Regulatory Updates



Federal

- The 2018 Farm Bill loophole is scheduled to close on November 12, 2026, subject to legislative revision before the effective date*, with products subject to total THC testing, a 0.4 mg per-container cap and a ban on synthetic cannabinoids
- The bipartisan CLIMB Act, introduced in March 2026, remains pending in the House Financial Services Committee

Virginia

- Anticipate the regulatory framework for adult-use sales will be finalized in early 2027; Retail sales expected to commence on July 1, 2027
- HB 30 went effective August 15, 2026, which eliminates state's 25:1 CBD-to-THC exception for hemp products, leaving a maximum of 0.3% total THC and 2 mg total THC per package for covered hemp products

Ohio

- SB 56 went effective March 20, 2026, which bans the manufacture and sale of “intoxicating hemp” products (e.g., delta-8, THC/CBD drinks, gummies), forcing all THC products into the state’s licensed cannabis dispensary system and removing them from gas stations, smoke shops and online sales

Illinois

- Gov. J.B. Pritzker signed SB 3222 in June 2026. The legislation immediately restricts intoxicating-hemp sales to consumers 21+, with major portions of the new Illinois Hemp Act taking effect November 12, 2026 (0.3% total THC standard and 0.4 mg THC limits per package)
- SB 3222 also provides for more operational flexibility for licensed cannabis companies

Pennsylvania

- PA Commonwealth Budget was passed with a spending number of \$50.1B. The need for an increased tax base is necessary due to no additional revenue for the PA legislature in the recently passed budget. Legislation is moving in the Senate and bipartisan adult-use bills have been filed in the House
- While adult-use legalization efforts have not yet produced enacted legislation, there has been movement on establishing a dedicated regulatory framework for cannabis oversight and alignment with federal law around intoxicating hemp through SB 49

* The Senate-passed Continuing Resolution (CR) could delay most federal hemp restrictions from November 12, 2026, to December 11, 2026, subject to final congressional approval and enactment

.Jushi

Appendix

Jushi Leadership Team



Jim Cacioppo

CEO, Chairman & Founder



Jon Barack

President, Chief
Revenue Officer,
Corporate Secretary
& Founder



Michelle Mosier

Chief Financial Officer

Q2 2026 Key Financial Metrics



Scan to check out the latest financials now on your phone!
[Financials and Filings :: Jushi Holdings Inc. \(JUSH\) \(jushico.com\)](#)




US\$ Millions, prepared under U.S. GAAP

Revenues




US\$ Millions, prepared under U.S. GAAP

Gross Profit



US\$ Millions, prepared under U.S. Non-GAAP ⁽¹⁾

Adjusted EBITDA



⁽¹⁾ See "Reconciliation of Non-GAAP Financial Measures" and "Reconciliation of Net Income (Loss) to Adjusted EBITDA and Adjusted EBITDA Margin"

Capitalization Summary



Scan to check out the latest financials now on your phone!
Financials and Filings :: Jushi Holdings Inc. (JUSH) (jushico.com)

(Amounts in millions, except share and per share amounts)

June 30, 2026

Cash ⁽¹⁾	\$35.5M
Total Debt ⁽²⁾	\$219.8M
Debt, Net Cash	\$184.3M
June 30, 2026	
Subordinate Voting Shares Outstanding	199,698,263
Options	26,917,919 ⁽³⁾
Warrants	79,494,087 ⁽⁴⁾
Fully Diluted Shares Outstanding	306,110,269

Operating Cash Flow

- Cash flows provided by operations for the first 6 months of 2026 were \$9.4 million

Debt

- Debt subject to repayment in 2026 is ~\$4.3 million as of June 30, 2026

Capital Expenditure

- Q2 2026 capital expenditures totaled ~\$3.9 million
- In 2026, the Company expects maintenance and growth capital expenditures to be ~\$10 million – \$13 million ⁽⁵⁾

(1) Includes cash, cash equivalents, and restricted cash (2) Excludes leases and property, plant and equipment financing obligations; this amount also excludes \$21.5 million notes payable to Sammartino, as the Company currently has no obligation to repay these notes.; (3) Weighted Average Strike Price: \$0.74; (4) Weighted Average Strike Price: \$0.95; (5) Capital expenditures to support targeted initiatives across grower-processor footprint and select retail build-outs; balance reflects capital expenditures excluding the impact of any potential regulatory changes in Pennsylvania (e.g., Pennsylvania transitioning to adult-use) and planned Virginia warehouse expansion

Adjusted EBITDA Reconciliation

JUSHI HOLDINGS INC.

RECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED EBITDA

(in thousands of U.S. dollars)



Scan to check out the latest financials now on your phone!

Financials and Filings :: Jushi Holdings Inc. (JUSH) (jushico.com)

	Three Months Ended June 30,	
	2026	2025
NET LOSS	\$ (7,329)	\$(12,331)
Income tax (benefit) expense	(976)	9,928
Interest expense, net	9,886	10,219
Depreciation and amortization ⁽¹⁾	9,232	7,967
EBITDA (Non-GAAP)	\$10,813	\$15,783
Non-cash share-based compensation	312	374
Fair value changes in derivatives	(333)	187
Long-lived asset impairment	1,334	-
Losses on debt extinguishment/modification	39	-
Other (income) expense, net ⁽²⁾	1,178	(2,630)
Adjusted EBITDA (Non-GAAP)	\$13,343	\$13,714

(1) Includes amounts that are included in cost of goods sold and in operating expenses.

(2) Includes: (i) remeasurement of contingent consideration related to acquisitions; (ii) losses (gains) on legal settlements; (iii) losses (gains) on asset disposals; (iv) foreign exchange losses (gains); (v) indemnification asset adjustments related to acquisitions; and (vi) start-up costs.

Adjusted EBITDA Margin Reconciliation

JUSHI HOLDINGS INC.

CALCULATION OF ADJUSTED EBITDA MARGIN

(in thousands of U.S. dollars)



Scan to check out the latest financials now on your phone!

Financials and Filings :: Jushi Holdings Inc. (JUSH) (jushico.com)



	Three Months Ended June 30,			
	2026		2025	
Total revenue, net	\$	71,297	\$	65,046
Adjusted EBITDA (Non-GAAP)	\$	13,343	\$	13,714
Adjusted EBITDA Margin (Non-GAAP)		18.7%		21.1%

Disclaimers



JUSHI HOLDINGS INC. RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin

In addition to providing financial measurements based on GAAP, we provide additional financial metrics that are not prepared in accordance with GAAP. We use non-GAAP financial measures, in addition to GAAP financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate our financial performance. These non-GAAP financial measures are EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin (each as defined below). We believe that these non-GAAP financial measures reflect our ongoing business by excluding the effects of expenses that are not reflective of our operating business performance and allow for meaningful comparisons and analysis of trends in our business. These non-GAAP financial measures also facilitate comparing financial results across accounting periods and to those of peer companies. As there are no standardized methods of calculating these non-GAAP measures, our methods may differ from those used by others, and accordingly, the use of these measures may not be directly comparable to similar measures used by others, thus limiting their usefulness. Accordingly, these non-GAAP measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.

EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin are financial measures that are not defined under GAAP. We define EBITDA as net income (loss), or “earnings”, before interest, income taxes, depreciation and amortization. We define Adjusted EBITDA as EBITDA before: (i) non-cash share-based compensation expense; (ii) inventory-related adjustments; (iii) fair value changes in derivatives; (iv) other (income)/expense items; (v) transaction costs; (vi) asset impairment; and (vii) gain/loss on debt extinguishment. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by total revenue. These financial measures are metrics that have been adjusted from the GAAP net income (loss) measure in an effort to provide readers with a normalized metric in making comparisons more meaningful across the cannabis industry, as well as to remove items that we do not believe represent the operations of the core business such as acquisition, transaction and other non-recurring costs that may otherwise distort the GAAP net income measure. Other companies in our industry may calculate this measure differently, limiting their usefulness as comparative measures.

Disclaimers



NO OFFERS

This presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities of the Company in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

THIRD PARTY INFORMATION

This presentation may include market and industry data which was obtained from various publicly available sources and other sources believed by the Company to be true. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this presentation or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. The Company does not make any representation as to the accuracy of such information.

REGULATORY

Potential investors are aware that the cannabis market is highly regulated, and that various permits and authorizations are necessary for the import, distribution, sale or other business activities related to medicinal cannabis. The respective regulations can be subject to change, which might affect the permits required. This presentation does not intend to advertise the products of the Company. Any reference to the products serves only the information of potential investors and shall not incite the purchase of the products.

COPYRIGHT

All brands and trademarks mentioned in this presentation and possibly protected by third parties are subject without restriction to the provisions of the applicable trademark law and the ownership rights of the respective registered owners. The mere fact that a trademark is mentioned should not lead to the conclusion that it is not protected by the rights of third parties. The copyright for published objects created by the Company remains solely with the Company. Any duplication or use of objects such as diagrams, sounds or texts in other electronic or printed publications is not permitted without the Company's agreement.

CURRENCY

All references to \$ or “dollar” in this presentation are references to USD, unless otherwise indicated.

Endnotes



- (1) (Virginia State Population) <https://www.census.gov/quickfacts/VA>
- (2) Esri (2026, 2031), Esri-Data Axle (2026), Esri U.S. BLS (2026)
- (3) (Health Service Area (“HSA”) II Population) <https://www.census.gov/quickfacts/fact/table/princewilliamcountyvirginia,manassascityvirginia,loudouncountyvirginia,fairfaxcountyvirginia,arlingtoncountyvirginia,alexandriacityvirginia/PST045222>; <https://www.census.gov/quickfacts/fact/table/manassasparkcitycountyvirginia,fallschurhcitycountyvirginia,fairfaxcitycountyvirginia/PST045225>
- (4) (Jushi’s total number of unique patient visits in Jushi’s HSA II footprint). Total number of unique individuals to visit Jushi dispensaries since the beginning of a medical program within HSA II. Virginia does not provide state level patient counts.
- (5) (Number of Pennsylvania dispensaries) <https://www.pa.gov/content/dam/copapwp-pagov/en/health/documents/topics/documents/programs/medical-marijuana/Medical%20Marijuana%20Dispensaries%20in%20Pennsylvania%20with%20Product.pdf>
- (6) (Pennsylvania State Population) <https://www.census.gov/quickfacts/PA>
- (7) (Pennsylvania Active Patients) <https://www.pa.gov/content/dam/copapwp-pagov/en/health/documents/topics/documents/programs/medical-marijuana/June%2024%202026%20MMAB%20Mtg.pdf>
- (8) (Ohio State Population) <https://www.census.gov/quickfacts/OH>



Thank You

Contact
investors@jushico.com